Tandem Diabetes Care (TNDM) Net Income towards Common Stockholders Growth (3y) (2016 - 2026)
Tandem Diabetes Care (TNDM) Net Income towards Common Stockholders Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn | -6.51% |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn | 7.96% |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn | -2.19% |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn | 64.73% |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn | - |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn | 29.56% |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 30.89% |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn | 60.12% |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn | - |
| 10 | Tandem Diabetes Care | 1.13 Bn | 557.61 Mn | 136.79 Mn | 45.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 45.19% |
| Dec 31, 2025 | 67.52% |
| Sep 30, 2025 | 24.42% |
| Jun 30, 2025 | -51.59% |
| Mar 31, 2025 | -107.09% |
| Dec 31, 2024 | -58.51% |
| Sep 30, 2024 | -82.10% |
| Jun 30, 2024 | -113.18% |
| Mar 31, 2024 | -103.62% |
| Dec 31, 2023 | -55.57% |
| Sep 30, 2023 | -51.79% |
| Jun 30, 2023 | -6.94% |
| Mar 31, 2023 | -102.72% |
| Dec 31, 2022 | -99.81% |
| Sep 30, 2022 | -156.52% |
| Jun 30, 2022 | -115.11% |
| Mar 31, 2022 | 13.85% |
| Dec 31, 2021 | 42.91% |
| Sep 30, 2021 | 29.42% |
| Jun 30, 2021 | 31.86% |